

The NCIN Oesophago-gastric service profiles

Nicky Coombes SSCRG and Service Profile Programme manager




Discuss...



- Oesophago-gastric service profiles: rationale, process, structure
 - Rationale
 - Process
 - Structure

A PERIODIC TABLE OF VISUALIZATION METHODS



Process Visualization Note: Depending on your location and connection speed it can take some time to load a pop-up picture.

>**☆**<

Fd

© Ralph Lengler & Martin J. Eppler, www.visual-literacy.org

Structure Visualization

Overview п Detail

> <

0 Detail AND Overview

< > Divergent thinking

Convergent thinking

>#< >☆< > 位 < >@< <=> Su Pc St H٥ OC. house of

game board

performance strategy map organisation supply demand cur charting chart 故 故 >@< >0< Pf Sg EG Μz portfolio strateric mintzberg's edgeworth

feedback quality diagram <(0)> <=> Z Ad zwicky's organigraph diagram

Ft Ma failure tree quadrant >#< Bm 0.6 decision

discovery

>#<

bcg matrix

Ld life-cycle diagram >#< Stc

strategy

>#<

>#< Po porter's five forces >#<

value chain

<m> s-cycle <=> >#<

Hy

hype-cycle

0 >#< Sm Is stakeholder

map

Sr

stakeholder

rating map

Tc ishikawa technology roadmap diagram >#< <=> Ta Sd taps spray

version 1.5

₩

diagram


http://www.visual-literacy.org/periodic_table/periodic_table.html


diagram


box


For example...











Profiles...



			1		Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	and	l	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	• •	588	NCDR	2010
Size	3 Number of NLCA patients - mesothelioma		329				191	1	•	585	NLCA	2011
			11				10	0	•0	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%	•	75%	NCDR	2010
(0	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
Demographics (based on newly gnosed patients, 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	•	46%	NCDR	2010
hic ewl nts,	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ 0	34%	NCDR	2010
rap on n atiei	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	•	100%	NLCA	2011
bas bas	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
co co	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	0	30%	NLCA	2011
ਰ	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	•	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	0	100%	NLCA	2011
	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes							NCPR	2010/11
Specialist	15	Peer review: Proportion of peer review indicators met	SA	85%			89%				NCPR	2010/11
Team	16	Peer review: are there immediate risks? (4)	SA	No							NCPR	2010/11
ream	17	Peer review: are there serious concerns? (4)	SA	No							NCPR	2010/11
	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%	◆	100%	NLCA	2011
	19	Number of urgent GP referrals for suspected cancer	406				293	0	•••	853	CWT	2010/11
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%	•	93%	NLCA	2011
Throughput and	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%	o	100%	NLCA	2011
pathology	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%	○ ♦	79%	NLCA	2011
patriology	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%	○ ◆	100%	NLCA	2011
	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%	♦ 0	97%	HES	2011
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%	○◆	100%	CWT	2012/13 Q2
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%	0.	100%	CWT	2012/13 Q2
Waiting times	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	•••	46%	CWT	2011/12
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%	• •	76%	CWT	2011/12
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%	↑ •	100%	CWT	2012/13 Q2
	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%	0 •	100%	NLCA	2011
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%	•0	38%	NLCA	2011
Drastics	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%	• O	45%	NLCA	2011
Practice	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC ,with stage I and II disease	40	48%	38%	59%	53%	0%	○ ◆	100%	NLCA	2011
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%	O	100%	NLCA	2011
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%	•	100%	NLCA	2011
Outcome	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%	•	68%	PBR SUS	2011/12
Outcomes and Recovery	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57	•	1.49	NLCA	2011
and Recovery	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40	• •	2.67	NLCA	2011
Patient	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%	.	100%	CPES	2011/12
Experience -	40	N		n/a				0%		78%	CPES	2011/12
CPES (8)	41	Number of survey questions and % of those questions scoring red and green (7) With the content of the conten	1 0	n/a				0%	1	69%	CPES	2011/12

Profiles... why?



					Percenta	ge or rate		Tr	ust rate or percentage compared to Eng	land	1	
Section	#	Indicator	No. of patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41	→ •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				191	1	• •	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				10	0	(O	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%		75%	NCDR	2010
6	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
s y 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○	46%	NCDR	2010
phics newly ents, 2	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	•	34%	NCDR	2010
Demographics (based on newly nosed patients, 2	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed of p	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	▼	100%	NLCA	2011
Derr (bas	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
agn	11	Number a									NLCA	2011
7	12	Number a	_				_		_		NLCA	2011
	13	Proportion • Assess and benchmar	k a v	vid	o ra	naa	Ωf	iní	formation at		NLCA	2011
	14	Peer revie A33C33 and Dentilinar	n a v	VIU	c la	uge	UI		ormation at		NCPR	2010/1
	15	Peer revit				_					NCPR	2010/1
Specialist Team	16	Peer revie									NCPR	2010/1
ream	17	Peer revie or conjugation love									NCPR	2010/1
	18	Peer revit organisation level								-	NLCA	2011
											NLCA	2011
	19	Number c								-	CWT	_
	19 20									-		_
0 1		Number a		o n	non	· of	on	0 F	ganication	-	CWT	2010/1
and		Number a	sse	ssn	nen	t of	an	or	ganisation	- - -	CWT NLCA	2010/1 2011
0 1	20 21	Number a Number a fat a glance, a	sse	ssn	nen	t of	an	or	ganisation	- - -	CWT NLCA NLCA	2010/1 2011 2011
and	20 21 22	Number a	sse	ssn	nen	t of	an	or	ganisation	- - - -	CWT NLCA NLCA NLCA	2010/1 2011 2011 2011
and	20 21 22 23 24	Number a	ISSE:	ssn	nen	t of	an	or	ganisation	- - - - -	CWT NLCA NLCA NLCA NLCA HES	2010/1 2011 2011 2011 2011 2011
	20 21 22 23 24 25	Number a Number a Number a Number a Sumber a Sum	ISS e :	ssn	nen	t of	an	or	ganisation	-	CWT NLCA NLCA NLCA NLCA HES CWT	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology	20 21 22 23 24 25 26	Number a O2 2012/ Q2 2012/							ganisation		CWT NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13
and pathology	20 21 22 23 24 25 26 27	Number a Stimate O2 2012/ O2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%	ganisation	46% 76%	CWT NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1
and pathology	20 21 22 23 24 25 26 27	Number a Number a Number a Number a Number a Stimated Cu2 2012/ Cu2 2012/ Curgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]			21% 19%	30% 33%	24% 39%	4% 0%	ganisation	76%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Sumber a Sum	103	25% 25%	21% 19% 78%	30% 33% 100%	24%	4%	ganisation		CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13
and pathology	20 21 22 23 24 25 26 27 28 29	Number a Number a Number a Number a Number a Stimated Cu2 2012/ Cu2 2012/ Curgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]	103 34 14 174	25% 25% 100% 53%	21% 19% 78% 47%	30% 33% 100% 58%	24% 39% 99% 60%	4% 0% 91% 36%	•	76% 100% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/13
and pathology	20 21 22 23 24 25 26 27 28 29 30 31	Number a Num	103 34 14	25% 25% 100%	21% 19% 78%	30% 33% 100% 58% 22%	24% 39% 99%	4% 0% 91%	•	76% 100%	CWT NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13 2011 2011/1 2011/1
and pathology	20 21 22 23 24 25 26 27 28 29 30 31 32	Number a Num	103 34 14 174 50	25% 25% 100% 53% 17% 26%	21% 19% 78% 47% 13% 20%	30% 33% 100% 58% 22%	24% 39% 99% 60% 16% 21%	4% 0% 91% 36% 0%	• • •	76% 100% 100% 38% 45%	CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number a Num	103 34 14 174 50 48	25% 25% 100% 53% 17%	21% 19% 78% 47% 13% 20% 38%	30% 33% 100% 58% 22% 33%	24% 39% 99% 60% 16% 21% 53%	4% 0% 91% 36% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45% 100%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2012/13 2011 2011 2011 2011 2011 2011 2011
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC with stage I and II disease	103 34 14 174 50 48 40 27	25% 25% 100% 53% 17% 26% 48%	21% 19% 78% 47% 13% 20%	30% 33% 100% 58% 22% 33% 59%	24% 39% 99% 60% 16% 21%	4% 0% 91% 36% 0% 0%	• • • • • • • • • • • • • • • • • • • •	76% 100% 100% 38% 45%	CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2012/13 2012/13 2011/1 2011/1 2011 2011 2011 2011 2011
and pathology /aiting times	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number a Num	103 34 14 174 50 48 40 27 28	25% 25% 100% 53% 17% 26% 48% 68% 58%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 33% 59% 80% 71%	24% 39% 99% 60% 16% 21% 53% 68% 55%	4% 0% 91% 36% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100%	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology laiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 13% 20% 38% 52% 44%	30% 33% 100% 58% 22% 333% 59% 80% 711%	24% 39% 99% 60% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0%		76% 100% 100% 38% 45% 100% 100% 68%	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT ANCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2010/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
and pathology /aiting times Practice Outcomes	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Sumbar a Number a Number a Sumbar a Sum	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 41%	21% 19% 78% 47% 133% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 15%		76% 100% 38% 45% 100% 100% 100% 68% 1.49	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 333% 59% 80% 711%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes and Recovery Patient	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Number a Num	103 34 14 174 50 48 40 27 28 23,053	25% 25% 100% 53% 17% 26% 48% 68% 58% 0.95	21% 19% 78% 47% 13% 20% 38% 52% 44% 0.82	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32%	4% 0% 91% 36% 0% 0% 0% 0% 057 0.57 0.40		76% 100% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2011 2011 2011 2011 2011 2011 201
and pathology /aiting times Practice Outcomes nd Recovery	20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number a Number a Number a Number a Number a Number a Stimatec Q2 2012/ Q2 2012/ Q2 2012/ Q2 2012/ Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	103 34 14 174 50 48 40 27 28 23,053 176 34%	25% 25% 100% 53% 17% 26% 48% 68% 58% 41% 0.95	21% 19% 78% 47% 13% 20% 38% 44% 41% 0.82 0.97	30% 33% 100% 58% 22% 33% 59% 80% 71% 41%	24% 39% 99% 60% 16% 21% 53% 68% 55% 32% 1.0	4% 0% 91% 36% 0% 0% 0% 0% 15% 0.57		76% 100% 38% 45% 100% 100% 100% 68% 1.49 2.67	CWT NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/ 2011 2011 2011 2012/1: 2012/1: 2011/1: 2011/1: 2011 2011 2011 2011 2011 2011 2011 20

O-G profiles – process (1)



- Aim: Benchmark and assess trust/MDT for commissioning & clinical review
- Published September 2013 (developed from similar Breast/Colorectal/Lung profiles published Dec 2011, Feb 2013)
- A NCIN / London KIT co-production in partnership with NCPR and NOGCA
- Hosted in the Cancer Commissioning Toolkit

O-G profiles – process (2)



Routinely collected data

- Cancer registry, CWT, NOGCA, CPES, HES, Peer Review
- Roughly half indicators generic, half specialist.
- Specialist indicators largely drawn from NOGCA
- Indicators Incorporate Clinical Lines of Enquiry

Profile anatomy



					Percenta	ge or rate		Tru	ust rate or percentage compared to Eng			
Section	#	Indicator	patients/ cases or value	Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				20	41	♦ 0	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	329				19	1	• 0	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma	11				1	0	· ·	31	NLCA	2011
	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%	•	75%	NCDR	2010
6 5		Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%	•	100%	NCDR	2010
s 2010)	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%	○	46%	NCDR	2010
Demographics (based on newly diagnosed patients, 20	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%	→ ○	34%	NCDR	2010
rap on n atie	8	Male patients (from #1)	161	53%	47%	58%	55%	43%	0 •	72%	NCDR	2010
ed o	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%	▼	100%	NLCA	2011
bas lose	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%	• •	68%	NLCA	2011
agn (11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%	0	30%	NLCA	2011
ō	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%	○◆	80%	NLCA	2011
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%	O	100%	NLCA	2011
	14	Peer review: Doe			_						NCPR	2010/
01-11-4	15	Peer review: Prop. Indicator		Nu	mbe	are	9%		•			
Specialist Team	16	Peer review: are		Nu	IIID	, 0			Spine chart &			000
		Peer review; are						١	Spille Cliait &		SOUI	(:6:
	17			4							<i>-</i>	
		Number and prop descriptions		rato	es. a	and	9%		-	(_	
	18	Number of urgen descriptions	!	rate	es, a	and	9% 293		-	(_	
	18 19	Number and prop Number of urgen Number and proportion of patients (from #2) with confirmed NSCLC			•		99 29 29		range of data	(!!	_	
hroughput	18 19 20	Number of urgeni			•		99 29 29 29		-	(<u>K</u> <u>K</u>	_	
hroughput and	18 19 20 21	Number of urgeni Number and proportion of patients (from #2) with confirmed NSCLC			es, a para		99 29: 29 29 99		-	(<u>k</u> <u>K</u> 10070	_	ites
hroughput and	18 19 20 21 22	Number of urgeni Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC			•		99 29 29 29 99 779	U%	-	(<u>k</u> <u>K</u> 16070	Da	ites
hroughput	18 19 20 21 22 23	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	C	om	para	ator	9%	U% 0%	range of data	(k <u>k</u> 1607 79%	NLCA	201- 201- 201-
hroughput and	18 19 20 21 22 23 24	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis	C (om	para 64%	ator:	99 779	0% 0% 52%	range of data	160% 79%	NLCA NLCA	201/ 201/ 201/ 201/ 201/
hroughput and	18 19 20 21 22 23 24 25	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental]	228 94	om 69% 47%	para 64% 40%	74% 54%	9% 77% 37%	0% 0% 52% 2%	range of data	79% 100% 100%	NLCA NLCA HES	201 201 201 201 2012/13
hroughput and pathology	18 19 20 21 22 23 24 25 26	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	228 94 135	69% 47% 96%	para 64% 40% 92%	74% 54% 98%	99 779 379 979	0% 0% 52% 2% 88%	range of data	100% 79% 100% 97%	NLCA NLCA HES CWT	201 201 201 201 2012/13 2012/13
hroughput and pathology	18 19 20 21 22 23 24 25 26 27	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	228 94 135 15	69% 47% 96% 73%	64% 40% 92% 52%	74% 54% 98% 87%	9% 77% 37% 97% 80%	0% 0% 52% 2% 88% 0%	range of data	100 /o 79% 100% 97% 100% 100%	NLCA NLCA HES CWT	201 201 201 201 2012/13 2012/13 2011/
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] 02 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks 02 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	228 94 135 15	69% 47% 96% 73% 25%	64% 40% 92% 52% 21%	74% 54% 98% 87% 30%	99 779 379 979 809 249	0% 0% 52% 2% 88% 0% 4%	range of data	79% 100% 97% 100% 100% 46%	NLCA NLCA NLCA HES CWT CWT	201 201 201 201 2012/13 2012/13 2011/ 2011/
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental]	228 94 135 15 103 34	69% 47% 96% 73% 25% 25%	64% 40% 92% 52% 21% 19%	74% 54% 98% 87% 30% 33%	99 779 379 979 809 249 399	0% 52% 2% 88% 0% 4%	range of data	100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA CWT CWT CWT	201 201 201 2012/13 2012/13 2011/1 2011/1 2011/1
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29 30	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat	228 94 135 15 103 34	69% 47% 96% 73% 25% 25% 100%	64% 40% 92% 52% 21% 19% 78%	74% 54% 98% 87% 30% 33% 100%	9% 77% 37% 97% 80% 24% 39% 99%	0% 0% 52% 2% 88% 0% 4% 0% 91%	range of data	79% 100% 97% 100% 100% 46% 76% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT	201- 201- 201- 201- 2012/13 2012/13 2011/ 2011/ 2012/13 2012/13
hroughput and oathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	228 94 135 15 103 34 14	69% 47% 96% 73% 25% 25% 100% 53%	64% 40% 92% 52% 21% 19% 78% 47%	74% 54% 98% 87% 30% 33% 100% 58%	9% 77% 37% 97% 80% 24% 39% 99% 60%	0% 52% 2% 88% 0% 4% 0% 91% 36%	range of data	79% 100% 97% 100% 100% 100% 46% 76% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA	2011 2011 2011 2012/13 2012/13 2011/1
hroughput and pathology	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 73% 25% 25% 100% 53%	64% 40% 92% 52% 21% 19% 78% 47%	74% 54% 98% 87% 30% 100% 58%	99 779 379 979 809 249 399 999 609 169	0% 52% 2% 88% 0% 4% 0% 91% 36%	range of data	100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA	2011/ 2011/ 2011/ 2012/13 2012/13 2011/ 20
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC	228 94 135 15 103 34 14 174 50	69% 47% 96% 73% 25% 25% 100% 53% 17%	64% 40% 92% 52% 21% 19% 47% 47% 13%	74% 54% 98% 87% 30% 33% 100% 58% 22%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21%	0% 52% 2% 88% 0% 4% 0% 91% 36% 0%	range of data	100% 100% 97% 100% 97% 100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA	2011/ 2011/ 2011/ 2012/13 2012/13 2011// 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/
hroughput and oathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	228 94 135 15 103 34 14 174 50 48	96% 47% 96% 73% 25% 100% 53% 17% 26% 48%	64% 40% 92% 52% 21% 19% 78% 47% 47% 20% 38%	74% 54% 98% 87% 30% 33% 100% 58% 22% 33% 59%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21% 53%	0% 0% 52% 28 88% 0% 4% 0% 91% 36% 0%	range of data	79% 100% 97% 100% 97% 100% 46% 76% 100% 38% 45% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA	2011/ 2011/ 2011/ 2012/13 2012/13 2011// 2011/ 2
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed SCLC with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40	69% 47% 96% 73% 25% 25% 100% 53% 17% 26% 48%	92% 52% 21% 19% 47% 13% 20% 38% 52%	74% 54% 98% 87% 30% 100% 58% 22% 33% 59%	9% 77% 37% 97% 80% 24% 39% 99% 60% 16% 21% 53% 68%	0% 52% 2% 88% 0% 4% 0% 36% 0% 0%	range of data	100 / 79% 100% 97% 100% 100% 100% 46% 76% 100% 100% 38% 45% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA	2011/ 2011/ 2012/13 2012/13 2012/13 2011/
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	228 94 135 15 103 34 14 174 50 48 40 27	69% 47% 96% 73% 25% 100% 53% 177% 26% 48% 68%	64% 40% 92% 52% 21% 19% 78% 47% 13% 20% 38% 52% 44% 41%	74% 544% 98% 87% 30% 33% 100% 100% 59% 80% 71% 41%	99 7779 377 977 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 91% 36% 0% 0% 0%	range of data	100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/12 2011/12 2012/13 2012/13 2012/13 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1 2011/1
nroughput and pathology siting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion resected of patients (from #2) with confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 73% 25% 100% 53% 17% 26% 48% 68% 58%	64% 40% 52% 52% 21% 19% 78% 47% 13% 20% 38% 52% 44% 41% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 7779 377 977 809 249 399 999 609 169 219 539 689	0% 52% 2% 88% 0% 4% 91% 36% 0% 0% 0% 0%	range of data	100% 97% 100% 97% 100% 46% 76% 100% 38% 45% 100% 100% 68%	NLCA NLCA NLCA HES CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA PBR SUS	2011/ 2011/ 2012/13 2012/13 2012/13 2011/
hroughput and pathology aiting times Practice	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed SCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed NSCLC No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with sale IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy First outpatient appointments and proportion of all outpatient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053	69% 47% 96% 73% 25% 25% 100% 53% 48% 68% 58% 41,009 51,43	64% 40% 52% 52% 21% 19% 78% 47% 13% 20% 38% 52% 44% 41% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 7779 377 977 809 249 399 999 609 169 219 539 689	0% 0% 52% 2% 88% 0% 91% 36% 0% 0% 0% 0% 0%	range of data	100% 100% 100% 100% 100% 100% 100% 100%	NLCA NLCA NLCA HES CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/ 2011/ 2012/13 2012/13 2012/13 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/ 2011/
hroughput and pathology aiting times	18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Number and proportion of patients (from #2) with confirmed NSCLC Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS Number and proportion of patients (from #2) with histological confirmation of diagnosis Estimated proportion of tumours with emergency presentations [experimental] Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] Cases treated that are urgent GP referrals with suspected cancer [experimental] Q2 2012/13: First treatment began within 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy No. and proportion resected of patients (from #2) excluding confirmed SCLC No. and proportion resected of patients (from #2) with confirmed SCLC, with stage I and II disease No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy No. and proportion of patients (from #2) with captient appointments NLCA: Median survival in days and adjusted hazard ratio for mortality NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	228 94 135 15 103 34 14 174 50 48 40 27 28 23,053 176 34%	69% 47% 96% 73% 25% 25% 100% 68% 68% 68% 41% 0.95	64% 40% 52% 52% 21% 19% 78% 47% 13% 20% 38% 52% 44% 41% 0.82	74% 544% 887% 30% 33% 100% 558% 22% 33% 59% 80% 71,111	99 779 379 979 809 249 399 999 609 169 211 539 689 559 329	0% 52% 2% 88% 0% 4% 0% 36% 0% 0% 0% 0% 0%	range of data	100 / 79% 100 / 79% 100 / 97% 100 / 46% 76% 100 / 46% 100 / 38% 45% 100 / 100 / 100 / 68% 1.49	NLCA NLCA NLCA NLCA CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2011/1 20

Profile anatomy



												_	
						Percenta	age or rate		Tre	ust rate or percentage compared to E	ngland		
Section	#	Indicator		No. of patients/ cases or value	Trust	Lower 95% confidence limit		England	Low- est	Range	High- est	Source	Period
	1	Number of newly diagnosed lung cancer patients per year, 2010 [_							* •	588	NCDR	2010
Size	2	Number of NLCA patients - lung cancer	Size – no.	nati	ion:	te d	iaar	106	ha	•	585	NLCA	2011
	3	Number of NLCA patients - mesothelioma		. pati		is u	iagi	103	Cu	* O	31	NLCA	2011
	4	Patients (Irom #1) aged 70*		100	02/0	, , ,	0 017	0 0170	JJ 70		/5%	NCDR	2010
aphics newly ients, 2010)	5	Patients (from #1) with recorded ethnicity		l 295	6 I 97%	ol 94%	%I 98%	93%	66%		100%	NCDR	2010
ics vly s, 20	6	Patients (from #5) with recorded ethnicity which is not White-British Patients (from #1) who are Income Deprived (2)	— Dation	4 44			ء الما ما	9	0%		46%	NCDR NCDR	2010
nev nev ients	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Male patients (from #1)	Patier	it ae	mo	ara	pnic	;s :	43%		34% 72%	NCDR	2010 2010
d on pat	9	Number and proportion of patients (from #2) with a stage assigned					•	,	36%		100%	NLCA	2010
Demographics (based on newly gnosed patients, 20	10	Number and proportion of patients, (norm #2) with a stage assigned Number and proportion of patients, excluding SCLC, with stage I or II	assign (inclu	idin/	n ei	and	2/PS	2	10%		68%	NLCA	2011
a) gua	11	Number and proportion of patients, excluding SCLC, with a stage IIIA	assign	aum	y Si	aye	<i>,</i> ,, ,	ا ا	4%	0	30%	NLCA	2011
<u>a</u>	12	Number and proportion of patients, excluding SCLC, with a stage IIIB		l 167	7 i 58%	53%	64%	62%	13%	0	80%	NLCA	2011
	13	Proportion of nationts (from #2) with a Performance Status assigned		286	87%	83%	90%	89%	2%	0	100%	NI CA	2011
	14	Peer review: Does the specialist team have full membershin? (3)		I 9A	Vac	,				I		NCPR	2010/1
													00404
Considiat	15	Pe A	D D	• .								NCPR	2010/1
Specialist	15 16	Specialist team -	Peer Rev	iew d	con	cer	ns a	and	CI	VS coverage		NCPR	
Specialist Team	15 16 17	Specialist team –	Peer Rev	iew (con	cer	ns a	and	CI	NS coverage			2010/1 2010/1
	15 16 17 18	Number and proportion of nationts (from #2) seen by CNS (5)	Peer Rev	iew (con	cer	ns a	and	CI	NS coverage	1100%	NCPR NCPR NLCA	2010/1 2010/1 2011
	15 16 17 18	Number and proportion of nations (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer	Peer Rev	iew (CON	cer	ns a	and 293 293	CI	NS coverage	853	NCPR NCPR NLCA CWT	2010/1 2010/1 2011 2010/1
Team	15 16 17 18 19 20	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent CP referrals for suspected cancer Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		853 93%	NCPR NCPR NLCA CWT NLCA	2010/1 2010/1 2011 2010/1 2011
Team Throughput and	15 16 17 18 19 20 21	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent CP referrals for suspected cancer Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati		406	63%	57%	/AL 68º/	293	0%		100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	15 16 17 18 19 20 21 22 23 24	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati	ut and pa	406	63%	/ - F	patie	293	0%		100%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2010/1 2011/1 2011 201
Team Throughput and	21 22	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati	ut and pa	406	63%	7 — F	patie	293	0%		100% 79%	NCPR NCPR NCPR NCA NCA NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2010/1 2010/1 2011 2011 20
Team	21 22 23 24 25	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Publication of	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2011/1 2010/1 2011 2011 20
Team Throughput and	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Publication of	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NCA NCA NLCA NLCA NLCA NLCA NLCA HES	2010/1 2010/1 2011/1 2010/1 2011/1 2011 201
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Sumber and proportion of pati Estimated proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency presentations [experticated to the proportion of tumours with emergency pre	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [experticated proportion of pati Publication of	ut and pa	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent	0 Ore	eakdown	100% 79%	NCPR NCPR NCPR NLCA CWT NLCA NLCA NLCA NLCA NLCA HES CWT CWT	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team hroughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 w 02 20 Urgen Waiting times pe 02 2012/13: First treatment began witnin 31 days of decision to treat No. and proportion of patients (from #2) receiving surgery, chemother	ut and pa imental eeks rformanc apy and/or radiotherapy	1 406 thol	Ogy 47%	7 — F	Datie 54%	293 ent 37% 6 37% 0n/ 99% 60%	2% 88% de	eakdown	100% 79% 100% 97% 1100%	NCPR NCPR NCPR NL CA NL CA NL CA NL CA NL CA NL CA CWT CWT CWT CWT CWT CWT CWT CWT CWT	2010/1 2010/1 2011/1 2011/1 2011/1 2011 201
Team Throughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 w 02 20 Urgen Waiting times pe Caset O2 2012/13: First treatment began witnin 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed	ut and pa imental eeks rformanc apy and/or radiotherapy sclc	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 ent 37% 37% 97% 60% 60% 16%	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT CWT NLCA	2010/1 2010/1 2011/1 2011/1 2011/1 2011 201
Team Throughput and pathology	21 22 23 24 25 26	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Q3 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental eeks rformanc apy and/or radiotherapy sclc	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 291 293 297 297 297 37% 37% 37% 37% 37% 37% 37% 37% 37% 37	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2011/1 2011 2011 20
Team hroughput and pathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SSC	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	1 406 thol	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 293 291 297 37% 37% 37% 6 60% 6 60% 6 21% 6 53%	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45% 100%	NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2011/1
Team hroughput and bathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Q3 2012/13: First treatment began within 31 days or decision to treat No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) with confirmed NSC	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 291 293 297 297 297 37% 37% 37% 37% 37% 37% 37% 37% 37% 37	2% 88% de 91% 36% 0%	eakdown	100% 79% 1 100% 97% 1100% 1100% 38% 45%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1
Team hroughput and bathology	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 02 2012/13: Urgent GP referral for suspected cancer seen within 2 w 02 20 Urgen Waiting times pe 02 2012/13: Pirst treatment began within 31 days of decision to treat No. and proportion of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2) excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL No. and proportion of patients (from #2) with confirmed SCL No. and proportion of patients (from #2) with confirmed SCLC receiving the patients (from #2) with confirmed SCL	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	Ogy 47% d c	7 — F	Datie 54% 7 ersi	293 293 293 291 297 37% 37% 37% 6 60% 6 60% 6 21% 6 53%	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team hroughput and pathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper 102 2012/13: Urgent GP referral for suspected cancer seen within 2 w 102 20 Urgen Cases 102 2012/13: First treatment began within 31 days or decision to treat 103 and proportion of patients (from #2) receiving surgery, chemother 104 No. and proportion resected of patients (from #2) excluding confirmed NSC 105 No. and proportion resected of patients (from #2), excluding confirmed SCI. 106 No. and proportion of patients (from #2) with confirmed SCI. 107 No. and proportion of patients (from #2) with confirmed SCI. 108 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 109 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI. 100 No. and proportion of patients (from #2) with confirmed SCI.	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC, with stage I and I g chemotherapy	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 45% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA NLCA NLCA CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2011/1 2011/1 2011 2011 20
Team nroughput and vathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL First outpatient appointments and proportion of all outpatient appoin NLCA: Median survival in days and adjusted hazard ratio for morta	ut and pa imental] eeks rformanc apy and/or radiotherapy ISCLC LC LC LC, with stage I and I	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 1100% 1100% 38% 45% 100% 100%	NCPR NCPR NI CA	2010/1 2010/1 2011/1
Team Troughput and pathology aiting times Practice Outcomes dd Recovery	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) with confirmed NSC No. and proportion resected of patients (from #2), excluding confirmed SC No. and proportion resected of patients (from #2), excluding confirmed SC No. and proportion of patients (from #2) with confirmed SCLC receiving surgery, changed the patients (from #2) with confirmed SCLC receiving surgery (from #2) with confirme	ut and pa imental] eeks rformanc apy and/or radiotherapy SCLC LC LC LC, with stage I and Ig chemotherapy Coutcome	tholo	9gy 47% d c	7 - p	patie	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 0% 0% 0%	eakdown tection rates	100% 79% 100% 97% 100% 100% 38% 45% 100% 100% 45% 100% 100% 100%	NCPR NCPR NCPR NCPR NLCA NLCA NLCA NLCA HES CWT CWT CWT CWT CWT CWT NLCA NLCA NLCA NLCA NLCA NLCA NLCA NLCA	2010/1 2010/1 2010/1 2010/1 2010/1 2010/1 2011/1 2011 201
Team Throughput and pathology aiting times	21 22 23 24 25 26 27 28 29 30 31	Number and proportion of patients (from #2) seen by CNS (5) Number of urgent GP referrals for suspected cancer Number and proportion of pati Number and proportion of pati Number and proportion of pati Estimated proportion of tumours with emergency presentations [exper G2 2012/13: Urgent GP referral for suspected cancer seen within 2 w Q2 20 Urgen Cases Q2 2012/13: First treatment began within 31 days or decision to treat No. and proportion of patients (from #2) receiving surgery, chemother No. and proportion resected of patients (from #2) excluding confirmed No. and proportion resected of patients (from #2), excluding confirmed NSC No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2), excluding confirmed SCL No. and proportion of patients (from #2) with confirmed SCL First outpatient appointments and proportion of all outpatient appoin NLCA: Median survival in days and adjusted hazard ratio for morta	ut and pa imental eeks rformanc apy and/or radiotherapy SCLC LC .C. with stage I and I g chemotherapy Outcome dignity (6) Dation	thologoup the state of the stat	Ogy 47% d c	7 - F 40% Onv 1 - 167% 47% acti	patie standard standa	293 293 293 297 298 37% 000/ 500/ 500/ 500/ 500/ 500/ 500/ 500	2% 88% de 91% 36% 0% 0%	eakdown tection rates	100% 79% 100% 97% 100% 100% 38% 45% 100% 100% 68% 1.49	NCPR NCPR NI CA	2010/11 2011 2011 2011 2011 2011 2011 20

Profiles – detail (1)



Section	#	Indicator
Sizo	OG1	Number of NOGCA patients
Size	G2	Number of newly diagnosed patients per year
	G3	Patients (from #G2) aged 70+
	G4	Patients (from #G2) with recorded ethnicity
Demographics	G5	Patients (from #G2) with recorded ethnicity which is not White-British
	G6	Patients (from #G2) who are Income Deprived (1)
	G7	Male patients (from #G2)

Profiles – detail (2)



	G8	Peer review: Does the specialist team have full membership? (2)
	G9	Peer review: Proportion of peer review indicators met
Specialist Team	G10	Peer review: are there immediate risks? (3)
	G11	Peer review: are there serious concerns? (3)
	G12	CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6)
Throughout	G13	Number of urgent GP referrals for suspected cancer
Throughput	G14	Estimated proportion of tumours with emergency presentations [experimental]
	G15	Urgent GP referrals for suspected cancer seen within 2 weeks
	G16	Treatment within 62 days of urgent GP referral for suspected cancer
Waiting times	G17	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]
	G18	Cases treated that are urgent GP referrals for suspected cancer [experimental]
	G19	First treatment began within 31 days of decision to treat

Profiles – detail (3)



	OG2	Number of new oesophageal cases managed per year
	OG3	Number of new stomach cases managed per year
	OG4	Oesophageal cancer confirmed histology
	OG5	Stomach cancer confirmed histology
Duantia	OG6	Number of O-G resections *
Practice	OG7	Patients who had a CT scan
	OG8	Patients with EUS investigation
	OG9	Patients with palliative treatment intent
	OG10	NCPR Network Board compliance
	OG11	NCPR NSSG compliance

Profiles – detail (4)



	OG12	30 day mortality (adjusted)
	OG13	90 day mortality (adjusted)
Outcomes and	OG14	Oesophageal cancer relative survival one year
Recovery	OG15	Stomach cancer relative survival one year
	OG16	Reoperation (adjusted)
	OG17	Anastomotic leak (adjusted)
	G20	Patients surveyed & % reporting always being treated with respect & dignity (6)
Patient Experience - CPES (4)	G21	Number of viable survey questions and % of those questions scoring red (7)
	G22	Number of viable survey questions and % of those questions scoring green (7)

O-G profiles overview



- Contains many relevant process, clinical, and outcome indicators – but new data gives new opportunities
- (The NOGCA adds a great deal of clinical value)
- Profile format is strong at assessing and benchmarking organisations (but not the whole story)



https://www.cancertoolkit.co.uk/

nickycoombes@nhs.net

020 7654 8148



Using information to improve quality & choice

www.ncin.org.uk